Health Care·Biotechnology·$7.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | -52.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.17 | N/A | -52.01% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized a commitment to long-term strategies without offering specific guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on long-term growth despite current challenges.
Halozyme's earnings report shows a significant miss on EPS, which may raise concerns among investors. However, the stock reacted positively, increasing by 1.02%. This could indicate that investors are optimistic about the company's long-term strategies despite the current earnings shortfall.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UGI CORP NEW
Nov 11, 2019